Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Not intended for U.S. and UK Media

Bayer to Present Data on Oncology Portfolio at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Presentations highlight Bayer's growing oncology pipeline

Leverkusen, May 18, 2011 – Bayer HealthCare announced today that data evaluating several of its investigational oncology compounds will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL. Bayer currently has 10 compounds in development in its oncology pipeline, including two being evaluated in Phase III clinical trials.

Of note, data will be presented during an oral session on BAY 86-9766, the MEK inhibitor candidate currently in Phase II development in partnership with Ardea Biosciences. Data will also be presented on Alpharadin, Bayer's investigational alpha-pharmaceutical currently in Phase III development for the treatment castration-resistant prostate cancer that has spread to the bone, and regorafenib, Bayer's investigational compound currently being evaluating in Phase III clinical trials for the treatment of colorectal cancer (CRC) and gastrointestinal stromal tumors (GIST).

"Bayer has built a rich pipeline of oncology compounds, including several in late-stage development, and our researchers are working tirelessly to advance their development with the goal of bringing them to patients as quickly as possible," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. "At ASCO, we are presenting research that supports the clinical potential of these compounds, which have been designed to combat the complex nature and pathomechanism of different cancers."

Studies evaluating Bayer's investigational oncology compounds being presented at ASCO include:

Alpharadin

- *Alkaline Phosphatase (ALP) Normalization and Overall Survival in Patients With Bone Metastases From Castration-Resistant Prostate Cancer (CRPC) Treated with Radium-223 (Alpharadin)*
    - Abstract #4620, Genitourinary Cancer Poster Session
    - Sunday, June 5, 8:00 am - 12:00 pm, Hall A, Poster Board 7D

Regorafenib

- *Phase I Study of Regorafenib Sequentially Administered with Either FOLFOX or FOLFIRI in 1st/2nd Line Colorectal Cancer Patients*
    - Abstract #3585, Gastrointestinal (Colorectal) Cancer Poster Session
    - Saturday, June 4, 8:00 am - 12:00 pm, Hall A, Poster Board 16A

- *Exploring the Relation between Overall Survival (OS) and Progression-Free Survival (PFS) in Gastrointestinal Stromal Tumor (GIST) via Meta-Analysis*
    - Abstract #10058, Sarcoma Poster Session
    - Sunday, June 5, 8:00 am - 12:00 pm, Hall A, Poster Board 47A

BAY 86-9766 (RDEA119), MEK Inhibitor

- *Safety, Pharmacokinetics and Pharmacodynamics Results from a Phase I Trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in Advanced Cancer Patients*
    - Abstract #3007, Developmental Therapeutics-Experimental Therapeutics Oral Session
    - Sunday, June 5, 11:00 am, Arie Crown Theater

BAY 80-6946, PI3K Inhibitor

- *A First-in-Human Phase I Study of Intravenous PI3K Inhibitor BAY 80-6946 in Patients with Advanced Solid Tumors: Results of Dose-Escalation Phase*
    - Abstract #3035, Developmental Therapeutics-Experimental Therapeutics Poster Session
    - Monday, June 6, 8:00 am - 12:00 pm, Poster Board 10H

About Oncology at Bayer

Bayer is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer. With several compounds in clinical development, Bayer's oncology portfolio demonstrates the Company's commitment to developing innovative cancer therapies.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Find more information at www.bayerpharma.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by the Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.